Table 3 Effect of low-dose ASA and clopidogrel on the risk of LGIB
Cases (n = 316) n (%) | Controls (n = 2,000) n (%) | Odds ratioa (95 % CI) | P value | |
|---|---|---|---|---|
ASA | ||||
Non-use | 74 (23.4) | 370 (18.5) | 1 (−) | |
Current use | 222 (70.3) | 1502 (75.1) | 0.96 (0.68–1.35) | 0.80 |
Duration | ||||
< 1 month | 11 (3.5) | 65 (3.3) | 0.79 (0.35–1.80) | 0.57 |
1–12 months | 97 (30.7) | 441 (22.1) | 1.20 (0.79–1.82) | 0.40 |
≥ 1 year | 114 (36.1) | 996 (49.8) | 0.83 (0.56–1.22) | 0.34 |
Dose | ||||
75 mg/day | 193 (61.1) | 1286 (64.3) | 0.96 (0.68–1.36) | 0.81 |
150 mg/day | 22 (7.0) | 178 (8.9) | 0.90 (0.51–1.57) | 0.70 |
300 mg/day | 7 (2.2) | 38 (1.9) | 1.30 (0.52–3.21) | 0.57 |
Recent use | 10 (3.2) | 59 (3.0) | 1.12 (0.51–2.44) | 0.77 |
Past use | 10 (3.2) | 69 (3.5) | 0.76 (0.36–1.60) | 0.47 |
Clopidogrel | ||||
Non-use | 200 (63.3) | 1529 (76.5) | 1 (−) | |
Current use | 95 (30.1) | 318 (15.9) | 1.86 (1.34–2.57) | <0.01 |
Duration | ||||
< 1 month | 9 (2.8) | 25 (1.3) | 2.40 (0.94–6.13) | 0.07 |
1–12 months | 44 (13.9) | 148 (7.4) | 1.51 (0.97–2.36) | 0.07 |
≥ 1 year | 42 (13.3) | 145 (7.3) | 2.12 (1.37–3.27) | <0.01 |
Dose | ||||
75 mg/day | 84 (26.6) | 286 (14.3) | 1.82 (1.30–2.55) | <0.01 |
≥ 150 mg/day | 11 (3.5) | 32 (1.6) | 2.15 (1.01–4.58) | 0.05 |
Recent use | 8 (2.5) | 40 (2.0) | 1.30 (0.58–2.94) | 0.52 |
Past use | 13 (4.1) | 113 (5.7) | 0.80 (0.43–1.48) | 0.47 |
Dual antiplatelet therapy | ||||
Non-use of both ASA and clopidogrel | 40 (12.7) | 237 (11.9) | 1 (−) | |
Current use of both ASA and clopidogrel | 57 (18.0) | 190 (9.5) | 1.63 (0.95–2.81) | 0.08 |
Current ASA use and non-current clopidogrel use | 165 (52.2) | 1312 (65.6) | 0.84 (0.54–1.32) | 0.46 |
Current clopidogrel use and non-current ASA use | 38 (12.0) | 128 (6.4) | 1.56 (0.88–2.74) | 0.13 |